HomeIMAGING
IMAGING
Medical Device News Magazine reports diagnostic imaging news. Keep up-to-date on new imaging developments.
Elucid Announces Fifth Medicare Administrative Contractor to Cover AI Coronary Plaque Analysis
“This latest expansion of coverage by Noridian means that even more patients could be positively impacted by PlaqueIQ, which offers the only non-invasive measurement of lipid-rich necrotic core, a vulnerable, high-risk component of plaque that can lead to heart attack and stroke,”4 said Kelly Huang, CEO of Elucid. “These recent decisions from five of the seven MACs recognize the importance of new technologies like ours that can help quantify and classify coronary artery plaque to help physicians reduce the clinical and economic burden of cardiovascular disease.”
Mediso Introduces True Theranostic TheraMAX SPECT/CT
The TheraMAX is equipped with three, large surface detectors (up to 5x larger than 12-detector CZT systems) surrounding the patients completely (360°). The 15.9mm thick NaI crystals ensure improved sensitivity for high energy photons, while the high-density sensor arrangement (123 PMT per detector head) allows high spatial resolution leading to PET-like image quality in all NM applications.
Pioneering Hospitals Take Major Steps Towards Decarbonizing Healthcare with Philips
“Good healthcare has to be environmentally sustainable, which means words and good intentions urgently need to be turned into positive actions. Philips is committed to co-creating solutions that drive measurable, impactful change. By working with like-minded action leaders around the world, sharing with them our expertise in sustainable healthcare operations, we are helping them to take critical and tangible steps toward a greener future, while at the same time enhancing patient care,” said Robert Metzke, Global Head of Sustainability at Philips.
IVUS and iFR Technologies Receive Top-level Recognition in New ESC Guidelines, Reinforcing their Role In Optimizing Coronary Interventions and Patient Outcomes
The latest updates to these ESC guidelines emphasize the robust clinical evidence supporting the use of intravascular ultrasound (IVUS) and instantaneous wave-free ratio (iFR), both of which have demonstrated significant benefits in improving patient outcomes through numerous large-scale randomized trials like DEFINE FLAIR and iFR SWEDEHEART. The updates were announced at the recent ESC Congress in London, five years after the last update in 2019, and simultaneously published in the European Heart Journal.
Bracco Imaging S.A. and Arrayus Technologies Announce Agreement to Enhance Drug Delivery for Pancreatic Cancer Treatment Using Focused Ultrasound and Microbubble Technology
Under the terms of the agreement, Bracco Imaging will supply Arrayus with microbubbles for use in the development and commercialization of its focused ultrasound platform for pancreatic cancer.
AI Can Detect Lung Nodules that Could Lead to Lung Cancer Nearly 3 Years Before Symptoms & Actual Diagnosis | Study finds
The study conducted at the Phrapokklao Hospital’s Cancer Centre of Excellence in Bangkok, Thailand was led by Dr Passakorn Wanchaijiraboon, Medical Oncologist and Deputy Director using the Qure.ai chest X-ray AI solution qXR.
KA Imaging Reports: Study Demonstrates Reveal 35C’s Impact in the ICU: Enhanced Imaging, Faster Diagnosis, and Potential CT Diversion
This is a summary of a study using the Reveal 35C detector in the ICU, to be presented at this year’s American Society of Emergency Radiology Meeting reports KA Imaging.
MAUI Imaging Emerges From Stealth With $4 Million Department of Defense Contract To Support Trauma Medicine
MAUI Imaging CEO and co-founder David Specht. “The feedback we have received from physicians and technologists highlights the profound need for a new ultrasound-based technology that enables imaging of all types of tissues. That need is most pronounced in trauma medicine, which is a major focus of MAUI’s collaborative development efforts. Going forward, MAUI will be able to supply the volumetric imaging data for AI tools that predominantly come from CT and MRI.”
Life Molecular Imaging and PharmaLogic announce Neuraceq® availability in Denver
"By partnering with PharmaLogic and offering Neuraceq® in Denver, Life Molecular Imaging is excited to expand access of Neuraceq® for the detection of beta-amyloid plaques in the brain. We believe this additional access benefits physicians and patients, as well as our pharma partners for routine clinical and research use. We are excited to collaborate with Pharmalogic today and look forward to more opportunities in the future. " said Ludger Dinkelborg, Ph.D., Managing Director at LMI.
